La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the research and development of highly specific therapeutic products for the treatment of certain antibody-mediated diseases. These diseases, including autoimmune conditions, such as lupus and antibody-mediated thrombosis, are caused by abnormal B-cell production of antibodies that attack healthy tissues. Therapies for these autoimmune disorders address only symptoms of the disease or non-specifically suppress the normal operation of the immune system, which often results in severe, negative side effects and hospitalization. The Company's drug candidates, called Toleragens, will treat the underlying cause of many antibody-mediated diseases. Its clinical drug candidates are Riquent, previously referred to as LJP 394, a drug for the treatment of lupus, and LJP 1082, a drug for the treatment of antibody-mediated thrombosis.